Kymera Therapeutics, Inc. has grown revenue 27% a year over three years and 10% a year over five. Revenue growth, 3-year annual rate: +27% (Biotechnology median +17%). Revenue growth, 5-year rate: +10%, growth has picked up over the last three years. Years of annual history on file: 7, FY2019 to FY2025, as filed.

KYMRKymera Therapeutics, Inc.

Healthcare

$112.32+129% 1Y

$112.32

$50.8752 weeks$127.24

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +135% year on year, but operating margin narrowing (−756.5 points).

1 good, 1 to watch, 1 without data

Revenue trend+135% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +10% a year.

Margin direction−756.5 points operating

Trailing-twelve-month operating margin, -1779.9% now against -1023.4% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is KYMR growing?

Kymera Therapeutics, Inc. has grown revenue 27% a year over three years and 10% a year over five.

+27%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +10%
Revenue growth, 5-year rate · +27% over three · growth has picked up over the last three years
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›